Psychedelic drug development is moving from a largely experimental field toward a suddenly much more compelling pharmaceutical industry, with
Continue Reading FDA Guidance, Clinical Pipelines, and the Emerging Deal Landscape of Psychedelic Therapeutics
Background
Artificial Intelligence (“AI”) has been utilized by innovative companies across the array of industry spaces, but its impact on
Continue Reading Key IP Licensing Considerations for AI Drug Discovery Platforms
Targeted protein degradation (TPD) is transforming drug discovery by leveraging the cell’s natural
Continue Reading Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy
As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and collaborators
Continue Reading mRNA/LNP Patent Litigation Update (Q1 2025)
In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact
Continue Reading Key Patent Considerations for Antibody Drug Conjugates (ADCs)
Although the Corporate Transparency Act (the “CTA”) is no longer halted by nationwide preliminary injunctions, U.S. companies and their beneficial
Continue Reading CTA Update: Domestic Reporting Companies Exempt from Reporting to FinCEN
For the past few months, the beneficial ownership reporting obligations under the Corporate Transparency Act (the “CTA”) have fluctuated between
Continue Reading Corporate Transparency Act Requirements Are Back: March 21, 2025 Deadline Looms
Co-authored by Sheena Wang and Ellie Purnell of HGF limited, “CRISPR and Agriculture” was originally published by Food and Drink
Continue Reading CRISPR and Agriculture
Only days after lifting the nationwide preliminary injunction, the Fifth Circuit Court of Appeals vacated their decision to stay the
Continue Reading Latest Update: Corporate Transparency Act Halted Again
As an update to our posts on the ongoing attempts to block the Corporate Transparency Act, on December 23, 2024
Continue Reading Update: Corporate Transparency Act Reinstated by Appeals Court: January 1 Deadline Looms